Evidence map›Paper›PMID 38307867›Full record

ArticleScientific data2024

A single cell RNAseq benchmark experiment embedding "controlled" cancer heterogeneity.

Maddalena Arigoni, Maria Luisa Ratto, Federica Riccardo, Elisa Balmas, Lorenzo Calogero, Francesca Cordero, Marco Beccuti, Raffaele A Calogero, Luca Alessandri

Abstract readDataset
In one paragraph

Article in Scientific data, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Benchmarking large-scale single-cell RNA-seq analysis.bioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours.International journal of molecular sciences · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maddalena Arigoni *Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Maria Luisa Ratto *Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Federica RiccardoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Elisa BalmasDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Lorenzo CalogeroDepartment of Electronics and Telecommunications (DET), Politecnico di Torino, Torino, Italy.
Francesca CorderoDepartment of Computer Science, University of Torino, Torino, Italy.ORCID 0000-0002-3143-3330
Marco BeccutiDepartment of Computer Science, University of Torino, Torino, Italy.
Raffaele A CalogeroDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. raffaele.calogero@unito.it.ORCID 0000-0002-2848-628X
Luca AlessandriDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) has emerged as a vital tool in tumour research, enabling the exploration of molecular complexities at the individual cell level. It offers new technical possibilities for advancing tumour research with the potential to yield significant breakthroughs. However, deciphering meaningful insights from scRNA-seq data poses challenges, particularly in cell annotation and tumour subpopulation identification. Efficient algorithms are therefore needed to unravel the intricate biological processes of cancer. To address these challenges, benchmarking datasets are essential to validate bioinformatics methodologies for analysing single-cell omics in oncology. Here, we present a 10XGenomics scRNA-seq experiment, providing a controlled heterogeneous environment using lung cancer cell lines characterised by the expression of seven different driver genes (EGFR, ALK, MET, ERBB2, KRAS, BRAF, ROS1), leading to partially overlapping functional pathways. Our dataset provides a comprehensive framework for the development and validation of methodologies for analysing cancer heterogeneity by means of scRNA-seq.

Indexed as

BenchmarkingLung NeoplasmsAlgorithmsCell Line, TumorGene Expression ProfilingHumansProto-Oncogene ProteinsSequence Analysis, RNASingle-Cell Gene Expression AnalysisProto-Oncogene Proteins

Identifiers

PMID38307867
PMCPMC10837414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.